



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/539,169	06/14/2005	Frank Brady	PZ02108	9282
36335 7590 02/02/2011 GE HEALTHCARE, INC. IP DEPARTMENT 101 CARNEGIE CENTER PRINCETON, NJ 08540-6231				
EXAMINER				
PERREIRA, MELISSA JEAN				
ART UNIT		PAPER NUMBER		
1618				
MAIL DATE		DELIVERY MODE		
02/02/2011		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/539,169

Applicant(s)

BRADY ET AL.

Examiner

MELISSA PERREIRA

Art Unit

1618

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 17 November 2010.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 4 and 15 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 4 and 15 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-940)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB-08)
Paper No(s)/Mail Date 9/20/10
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11/17/10 has been entered.

Claims and Previous Objections/Rejections

2. Claims 4 and 15 are pending in the application.

3. The rejection of claims 4 and 15 under 35 U.S.C. 103(a) as being unpatentable over Luthra et al. (US 2004/0236085) in view of Stevens et al. (WO01/14354) and Scheler (US 4,540,648) is maintained.


Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:


(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. Claims 4 and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Luthra et al. (US 2004/0236085) in view of Stevens et al. (WO01/14354) and Scheler (US 4,540,648).

6. Luthra et al. (US 2004/0236085) discloses a solid-phase process for the production of ^{18}F -radiolabelled tracers which are suitable for use as Positron Emission Tomography (PET) radiotracers (abstract; p1, [0001]; p6, [0099]). The process for the production of radiolabelled tracers comprise a.) treatment of a resin-bound precursor, SOLID SUPPORT-LINKER- I^+ -TRACER Y^- , with $^{18}\text{F}^-$ to produce the labeled tracer, ^{18}F -TRACER; b.) removal of excess $^{18}\text{F}^-$ by ion-exchange chromatography; c.) removal of any protecting groups; d.) removal of organic solvent; e.) formulation of the resultant ^{18}F -TRACER as an aqueous solution (p1, [0004-0006], [0008-0015]; p5, [0070-0076]). The SOLID SUPPORT may comprise polystyrene and the LINKER may comprise zero to four aryl groups (suitably phenyl) and/or a C_{1-6} alkyl and optionally one to four additional functional groups (not excluding

alkoxy), , etc. and may

further comprise an aryl group (suitably phenyl) adjacent to the I^+ . Preferred examples

include 

(p1, [0018-0019]; p5, [0079]). The SUPPORT-

LINKER of the disclosure encompasses the SUPPORT-LINKER of the instant claims

and Y⁻ (i.e. triflate) encompasses the Y⁻ (anion) of the instant claims. The solid-phase process provides for producing ¹⁸F-labelled tracers used for PET quickly and with high specific activity yet avoiding time-consuming purification steps. The solid-phase methods also lend themselves to automation with advantages of ease of production and greater throughput (p1, [0003]). Luthra et al. does not disclose a benzothiazole TRACER.

7. Stevens et al. (WO01/14354) discloses ¹⁸F-substituted benzothiazoles for use in PET (p5, lines 3-17).

8. Also, the 2-phenylbenzazoles of the disclosure comprises a halogen substituent, preferably fluorine, R¹, on the benzene ring of the benzazole nucleus (abstract; p2, lines 13+). The R¹halogen substituent will commonly represent F, preferably but not necessarily in the 5-position (p4, lines 25+). Fluorine substituted compounds of the disclosure may incorporate the isotope ¹⁸F and are used for imaging purposes, for example positron emitting tracers for us in PET (column 5, lines 3-17).

9. Scheler (US 4,540,648) discloses a benzothiazole/light sensitive compound linked to a solid support/film (i.e. polystyrene) via a coupler component (abstract; column 3, lines 25+; column 7, lines 5-11 and 60-66; claim 1). The polystyrene solid support encompasses the solid support of the disclosure as evidenced in the specification p6, lines 1-8.

10. At the time of the invention it would have been obvious to one ordinarily skilled in the art to substitute the benzothiazole/light sensitive compound of Stevens et al. and Scheler for the TRACER of Luthra et al. to generate a ¹⁸F radiolabelled benzothiazole

(derivative) via the polymer-bound/solid support of Luthra et al. as Stevens et al. teaches that ^{18}F -substituted benzothiazoles that are substituted on the benzene ring of the benzazole nucleus were known in the art at the time of the invention. The ^{18}F -substituted benzothiazoles are preferably but not necessarily in the 5-position and thus the ^{18}F may be substituted at any other position of the benzene ring of the benzazole nucleus. Also, it would have been obvious to one ordinarily skilled in the art to attach a benzothiazole (derivative) to the polystyrene solid support (Luthra et al.) as Scheler also teaches that benzothiazole may be linked to a polystyrene solid support via a coupler.

11. Luthra et al. and Stevens both teach of ^{18}F radiolabelled radiopharmaceutical agents for use in PET. It would have been predictable and advantageous to use the polymer-bound/solid support of Luthra et al. to radiolabel benzothiazoles with ^{18}F to avoid time consuming purification steps and allow for ease of production and greater throughput (Luthra et al.; p1, [0003], [0006]; p6, [0099]).

Response to Arguments

12. Applicant's arguments filed 5/14/10 have been fully considered but they are not persuasive.

13. Applicant asserts that Luthra et al. fails to teach or suggest the labeling of benzothiazole compounds, much less the regiospecific labeling of benzothiazole compounds. Hence Luthra et al. fails to teach or suggest Applicant's claimed regiospecific benzothiazole ^{18}F -labeling process.

14. The reference of Luthra et al. was not used to teach of benzothiazole tracers but was used to teach of the general solid-phase process for the production of ^{18}F -radiolabelled tracers which are suitable for use as Positron Emission Tomography (PET) radiotracers. The solid-phase process provides for producing ^{18}F -labelled tracers used for PET quickly and with high specific activity yet avoiding time-consuming purification steps. The solid-phase methods also lend themselves to automation with advantages of ease of production and greater throughput. The method steps of the solid-phase process encompasses the method steps of the process of the instant claims.

15. Scheler teaches that benzothiazole may be linked to a polystyrene solid support via a coupler.

16. Stevens et al. teaches of ^{18}F -substituted benzothiazoles were known in the art and used as PET tracers at the time of the invention. The ^{18}F -substituted benzothiazoles are preferably but not necessarily in the 5-position and thus the ^{18}F may be substituted at any other position of the benzene ring of the benzazole nucleus.

17. Therefore, at the time of the invention it would have been obvious to one ordinarily skilled in the art to attach a benzothiazole (derivative) to the polystyrene solid support such as that of Luthra et al. to avoid time consuming purification steps and allow for ease of production and greater throughput of a ^{18}F -substituted benzothiazoles, such as that of Stevens et al. for use in PET.

18. Applicant asserts that Stevens describes that their ^{18}F labeled compounds are prepared from corresponding iodo substituted compound. Stevens is silent as to Applicant's claimed process.

19. The reference of Stevens et al. was not used to teach of the method of preparing the ^{18}F -substituted benzothiazoles but was used to teach that ^{18}F -substituted benzothiazoles were known in the art at the time of the invention for use as PET radiotracers. The ^{18}F -substituted benzothiazoles are preferably but not necessarily in the 5-position and thus the ^{18}F may be substituted at any other position of the benzene ring of the benzazole nucleus.

20. The reference of Luthra et al. was used to teach of the general solid-phase process for the production of ^{18}F -radiolabelled tracers which are suitable for use as Positron Emission Tomography (PET) radiotracers. The solid-phase process provides for producing ^{18}F -labelled tracers used for PET quickly and with high specific activity yet avoiding time-consuming purification steps. The solid-phase methods also lend themselves to automation with advantages of ease of production and greater throughput.

21. Scheler teaches that benzothiazole may be linked to a polystyrene solid support via a coupler.

22. At the time of the invention it would have been obvious to one ordinarily skilled in the art to substitute the benzothiazole group of Stevens for the TRACER of Luthra et al. as one skilled in the art would have been capable of linking a benzothiazole to the polystyrene solid support via the coupler, such as LINKER-I⁺- of Luthra et al. as Scheler

explicitly states that benzothiazole may be linked to a polystyrene solid support via a coupler.

23. Therefore, at the time of the invention it would have been obvious to one ordinarily skilled in the art to attach a benzothiazole (derivative) to the polystyrene solid support such as that of Luthra et al. to avoid time consuming purification steps and allow for ease of production and greater throughput of a ^{18}F -substituted benzothiazoles, such as that of Stevens et al. for use in PET.

24. Applicant asserts that Scheler is wholly unconcerned with radiofluorination of benzothiazole compounds. Thus, one of skill in the art would not be motivated by either Stevens or Scheler to regiospecifically radiofluorinate a benzothiazole compound according to Applicant's claimed process.

25. The reference of Scheler was not used to teach of radiofluorination of benzothiazole compounds but was used to teach that benzothiazole may be linked to a polystyrene solid support via a coupler and thus it was known in the art at the time of the invention to link a benzothiazole to a polystyrene solid support via a coupler, such as LINKER-I* of Luthra et al.

26. The reference of Luthra et al. is concerned with the radiofluorination of a tracer for use in PET.

27. The reference of Stevens et al. was used to teach that ^{18}F -substituted benzothiazoles were known in the art at the time of the invention for use as PET radiotracers. The ^{18}F -substituted benzothiazoles are preferably but not necessarily in

the 5-position and thus the ^{18}F may be substituted at any other position of the benzene ring of the benzazole nucleus.

Conclusion

No claims are allowed at this time.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELISSA PERREIRA whose telephone number is (571)272-1354. The examiner can normally be reached on 9am-5pm M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael G. Hartley/
Supervisory Patent Examiner, Art Unit 1618
/Melissa Perreira/
Examiner, Art Unit 1618